Patents matching “formulation”

US 10828250

Topical formulation

LIMEWAY PHARMA DESIGN LIMITED · Granted Nov 10, 2020 · Expires Nov 5, 2040

US 10821146

Powder formulation having a function of enhancing immunity and method for preparing the same

INFINITUS (CHINA) COMPANY LTD. · Granted Nov 3, 2020 · Expires Oct 29, 2040

US 10821092

Viscous topical ocular formulations

Encompass Development, Inc. · Granted Nov 3, 2020 · Expires Oct 29, 2040

US 10820615

Powder formulation having a function of enhancing immunity and method for preparing the same

INFINITUS (CHINA) COMPANY LTD. · Granted Nov 3, 2020 · Expires Oct 29, 2040

US 10822429

Etanercept formulations exhibiting marked reduction in sub-visible particles

Coherus BioSciences, Inc. · Granted Nov 3, 2020 · Expires Oct 29, 2040

US 10813961

Powder formulation having a function of enhancing immunity and method for preparing the same

INFINITUS (CHINA) COMPANY LTD. · Granted Oct 27, 2020 · Expires Oct 22, 2040

US 10806740

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Oct 20, 2020 · Expires Oct 15, 2040

US 10806781

Compositions and methods for live, attenuated alphavirus formulations

Takeda Vaccines, Inc. · Granted Oct 20, 2020 · Expires Oct 15, 2040

US 10799585

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

US 10798955

Compositions of particulate coformulation

Nektar Therapeutics · Granted Oct 13, 2020 · Expires Oct 8, 2040

US 10792246

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

US 10792363

Anhydrous sodium thiosulfate and formulations thereof

Fennec Pharmaceuticals, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

US 10786554

Factor VIII polypeptide formulations

BIOVERATIV THERAPEUTICS INC. · Granted Sep 29, 2020 · Expires Sep 24, 2040

US 10786566

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted Sep 29, 2020 · Expires Sep 24, 2040

US 10780163

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

US 10772942

Lyophilized factor IX formulations

BIOVERATIV THERAPEUTICS INC. · Granted Sep 15, 2020 · Expires Sep 10, 2040

US 10772959

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

US 10772960

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

US 10772963

Etanercept formulations stabilized with xylitol

Coherus BioSciences, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

US 10765683

Stable formulations for parenteral injection of small molecule drugs

XERIS PHARMACEUTICALS, INC. · Granted Sep 8, 2020 · Expires Sep 3, 2040

US 10765691

Method for treating crohn's disease using triple antimicrobial all-in-one formulation

RedHill Biopharma Ltd. · Granted Sep 8, 2020 · Expires Sep 3, 2040

US 10758598

TPP-1 formulations and methods for treating CLN2 disease

BIOMARIN PHARMACEUTICAL INC. · Granted Sep 1, 2020 · Expires Aug 27, 2040

US 10758621

Liquid formulation comprising GM-CSF neutralizing compound

TAKEDA GMBH · Granted Sep 1, 2020 · Expires Aug 27, 2040

US 10751281

Auris formulations for treating otic diseases and conditions

The Regents of the University of California · Granted Aug 25, 2020 · Expires Aug 20, 2040